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Introduction 
 Bladder cancer, the fourth most common cancer in men and the ninth in women, places a 
significant global healthcare burden with over 350,000 new cases diagnosed worldwide per year 
and approximately 145,000 deaths (1, 2). In the United States 2.35% of individuals born today 
will be diagnosed with bladder cancer in their lifetime (3, 4). In addition, bladder cancer has 
been estimated to be one of the most expensive cancers to treat in the USA with $3.7 billion in 
direct costs (5). Tobacco smoking is the most important determined risk factor of bladder cancer, 
with 2- to 4-fold greater relative risk, and is a global concern due to expansion in tobacco use. 
Other risk factors include occupational and environmental carcinogen exposures (4, 6, 7).    
The urothelium is the transitional epithelial lining of the bladder and is where 90% of bladder 
cancers, referred to as Transitional Cell Carcinoma (TCC), are derived (8, 9).There are two types 
of transitional cell carcinoma which are thought to progress through different mechanistic 
pathways: a non-invasive variant which encompasses approximately 80% of urothelial 
carcinomas and an invasive variant. The non-invasive variant, when treated with surgical 
resection and local immunotherapy, has a 5-year survival rate of almost 90%. However, this 
cancer has an approximately 70% chance of recurring and a 10-20% chance of developing into 
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invasive disease (10). The invasive form has a grimmer prognosis with greater than 50% of 
patient death from metastases within two years of diagnosis. Treatment is unsuccessful in 95% of 
patients and the 5-year survival rate is approximately 6% (9).    
 Dietary factors may play a significant role in the development of bladder cancer. A 
landmark series of epidemiological studies (11-14) included an examination of fruit and 
vegetable intake and the incidence of bladder cancer, reporting that intake of cruciferous 
vegetables, particularly broccoli, had a strong inverse association with bladder cancer risk (12). 
When compared to those consuming <1 serving of broccoli/week, consumption of 1 
serving/week led to a decreased risk of 0.71 and ≥2 servings/week had a decreased risk of 0.61 
(p=.009). The next necessary step is to test these findings from epidemiological studies in pre-
clinical models and define mechanisms of action. 
 Broccoli (Brassica oleracea italica) is part of the cruciferous vegetable family and 
includes commonly consumed vegetables such as cauliflower, cabbage and brussel sprouts. 
Isothiocyanates are phytochemicals found in broccoli that have been shown to have anti-cancer 
effects. They include compounds such as sulforaphane, erucin, allyl isothiocyanate and iberin 
(15). In intact plants, isothiocyanates are stored as inert precursors called glucosinolates (16). 
Glucosinolates are converted to isothiocyanates when they are hydrolyzed by myrosinase, an 
enzyme that is released when the plant’s cell structure has been disrupted through chewing, 
chopping or digestion (17). Young broccoli plants, especially sprouts, have 20-50 times the 
levels of preventative glucosinolates than more mature market-stage plants (18). 
 Collectively, recently published data suggests that broccoli and broccoli sprout 
isothiocyanates can be absorbed by the body, may reach µM concentrations in the blood, 
accumulate in tissues and be maintained to achieve an anti-cancer effect (19). Some evidence 
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also shows that active ITCs are capable of reaching the bladder epithelium via the urine (20). 
However, there is a need for more in vivo pharmacokinetic and metabolic studies before such 
work can be applied and translated into humans. 
 There is growing evidence that cruciferous vegetables and their phytochemicals, 
including isothiocyanates, have anti-cancer properties. In vitro, broccoli isothiocyanates have 
been shown to inhibit viability in a multitude of human cancer cells, inducing apoptosis and cell 
cycle arrest (21-23). There are far fewer in vivo studies, with predominant work in cancers such 
as prostate and colon both showing inhibition of tumor growth as a result of broccoli 
phytochemical treatment (24-27). The bladder cancer field possesses very limited in vivo studies 
with broccoli, however one rat study using a freeze-dried aqueous extract of broccoli sprouts 
showed a dose-dependent inhibition of bladder cancer development induced by the carcinogen 
BBN and maintenance of normal tissue (24). Scant clinical studies exist, however the few that do 
show a lack of toxicity of broccoli isothiocyanate administration in humans (28, 29). Clearly, 
there is a great need for additional in vivo pre-clinical studies in order to test the potential of 
these foods for the development of human clinical trials.  
 Most mechanistic studies of the potential preventative effects of broccoli and ITCs focus 
on their ability to induce phase II enzymes and inhibit Phase I enzymes, leading to the 
detoxification of carcinogens as well as the prevention of carcinogen activation, respectively (30, 
31). However, in vitro and in vivo studies, where cancer is inhibited by these compounds without 
carcinogen induction, indicates that there must be other mechanisms of action at play. There is 
recent evidence, that ITCs may act as histone deacetylase inhibitors (26, 32-34) altering 
epigenetic regulation of gene expression over time. Overall, however, much research needs to be 
done in order to uncover how these powerful compounds may act as anti-bladder cancer agents.   
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The epidemiological association between high cruciferous vegetable intake and decreased risk of 
bladder cancer warrants further preclinical studies of the potential of these compounds to inhibit 
bladder cancer utilizing in vitro and in vivo models. The ability of broccoli compounds to inhibit 
non-carcinogen induced bladder cancer has not been well-studied.  
 Herein we report that broccoli isothiocyanates can inhibit human bladder cancer cell 
viability in vitro in a panel of bladder cancer cell lines ranging from superficial (RT4) to invasive 
(J82, UMUC3) as well as induce apoptosis and modulate the cell cycle, leading to cell 
accumulation in the G2/M phase. In addition, UMUC3 xenograft mice treated with either 4% 
freeze-dried broccoli sprouts, 2% freeze-dried broccoli sprouts extract; or gavaged daily with 
295 µmol/kg sulforaphane or 295 µmol/kg erucin lead to a significant at least 40% reduction in 
tumor weight after 2 weeks of treatment when compared to the control groups and that this 
inhibition was associated with inhibition of cell proliferation (Ki67 staining) and induction of 
apoptosis (PARP cleavage). Finally, we show that broccoli isothiocyanates are readily absorbed 
and metabolized in mouse blood and reach micromolar concentrations and that there is an 
apparent interconversion between sulforaphane and erucin metabolites in vivo.  
 
Materials and Methods 
Reagents:  Sinigrin, glucoiberin, progoitrin, glucoerucin, and glucotropaeolin were purchased 
from the Department of Chemistry, The Royal Veterinary and Agricultural University, Denmark. 
Thioglucosidase (myrosinase) extracted from white mustard seed and BDT were purchased from 
Sigma-Aldrich (St. Louis, MO).  All solvents used were of HPLC grade and were purchased 
from Fisher Scientific (Fairlawn, NJ).  Organic broccoli and BroccoSprouts® were purchased 
fresh from a local supermarket (Whole Foods, Columbus, Ohio).  N-acetyl cysteine (NAC) was 
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purchased from Fluka (Switzerland). Sulforaphane (SFN), erucin, iberin, phenethyl ITC, and 
allyl ITC were purchased from LKT Laboratories, Inc. (St. Paul, Minnesota).  Iberverin was 
purchased from Alfa Aesar (Ward Hill, MA).  All solvents used were of HPLC grade and were 
purchased from Fisher Scientific (Fairlawn, NJ).   
 
Extraction of glucosinolates for quantification: A modified previously reported procedure was 
used to extract the GLUs from the freeze-dried vegetables (35). Briefly, broccoli and broccoli 
sprouts were frozen at -80°C and lyophilized for 48h.  The freeze-dried vegetables were milled 
into fine powders using a mortar and pestle and samples were extracted in 70% aqueous 
methanol and sonicated for 15 min at 70°C and centrifuged at 15,000g for 15 min, and the 
supernatant was removed.  Supernatants were then concentrated under vacuum with a rotary 
evaporator (Büchi R110) with a maximum temperature of 50°C and then frozen at -80°C, and 
lyophilized until dry.  Triplicate samples were extracted and analyzed, and data are represented 
as average ± standard deviation. 
 
LC-ESI/MS/MS of intact glucosinolates: All mass spectra were obtained using a Quattro Ultima 
ion-tunnel mass spectrometer (Micromass, Manchester, UK) coupled to a Waters 2696 HPLC 
system equipped with a 996 photo-diode array (PDA) detector (Waters Associates, Milford, 
MA).  HPLC separation was performed on a 250 × 4.6 mm (5 µm) Luna C18 (2) reversed-phase 
column (Phenomenex Ltd., Torrance, CA) with a Phenomenex security guard column.  A linear 
gradient mobile phase from 100% A (water containing 0.5% trifluoroacetic acid) to 15% B 
(acetonitrile) in 10 min, to 40% B in 5 min, to 50% B in 5 min, and returned to 100% A in 5 min 
was used to elute the analytes at a flow rate of 1 ml/min. Approximately 100 µL/min of the 
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HPLC eluant separated by a micro-splitter (Upchurch Scientific, Oak Harbor, WA) was 
delivered to the Z-spray ESI source.  Negative ion tandem mass spectrometry (MS/MS) was 
conducted to detect GLUs with selected reaction monitoring (SRM).  The mass spectrometer was 
tuned by direct infusion of standard sinigrin producing maximum abundant precursor ion m/z 
358 ([M-H]-) and fragment ion m/z 97 ([SO3H]-) signals (approximately in equivalent 
abundance) during MS/MS.  The mass spectrometric conditions are as follows: capillary, 2.35 
kV; cone voltage, -35 V (RF-1, 50 V); desolvation gas temperature, 450 °C at a flow of 16.5 
L/min; source temperature, 120 °C; collision energy, 18 eV. The following transitions were used 
to assay ten individual GLUs: glucoiberin (422>97), sinigrin (358>97), progoitrin (388>97), 
glucoerucin (420>97), glucoraphanin (436>97), gluconapin (372>97), glucoalysin (450>97), 
glucobrassicin (447>97), neoglucobrassicin (477>97), 4-methoxy glucobrassicin (477>97).  
Glucotropaeolin (408>97), not found in cruciferous vegetables and previously used as an internal 
standard in a European Committee method (12), was used as the internal standard in the current 
study. A dwell time of 0.08 s was used for each transition. Standard calibration curves were 
established by triplicate analyses (seven concentration levels), and deviations from the mean 
calculated concentrations over three runs were within 15% from the nominal concentrations. At 
the lower limit of quantification (LLOQ) level, the deviation was within 20%. For GLUs in 
vegetables, glucoiberin, sinigrin, progoitrin, and glucoerucin were quantified using their 
corresponding standard calibration curves; because standards were not available for the 
remaining compounds, glucoraphanin and glucoalysin were estimated using the calibration curve 
of glucoiberin, based on the structural similarities of the three compounds.  Similarly, gluconapin 
was estimated using the calibration curve of sinigrin. The three indole GLUs (glucobrassicin, 
neoglucobrassicin, and 4-methoxy glucobrassicin) were estimated using the calibration curve of 
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the internal standard (glucotropaeolin).  To avoid any irreproducibility caused by conditions such 
as HPLC eluant splitting ratio, temperature, or the detector condition, all the analyses were 
conducted in sequence without disruption. 
 
Extraction of glucosinolates and conversion to isothiocyanates: To ensure consistency among 
extracts, a large scale method was used for extractions.  Twelve 1.5 g samples of freeze-dried 
broccoli or broccoli sprout powder were extracted in 50-ml screw-top centrifuge tubes using 25 
ml 70% aqueous methanol and sonicated for 15 min at 70°C.  After being cooled in an ice bath, 
the extract was centrifuged at 15,000g for 15 min, and the supernatant was removed using a 
syringe.  The extraction procedure was completed three times and the supernatants of samples 1-
6 and 7-12 were combined; samples 1-6 were intended for GLUs and samples 7-12 were 
intended for ITCs.  400 ml of each of the two extracts were concentrated under vacuum to ~120 
ml with a rotary evaporator (Büchi R110) with a maximum temperature of 50°C.  Both extracts 
were divided evenly among 36 11-ml glass screw-top vials (72 vials total), frozen at -80°C, and 
lyophilized until dry.  Two GLU samples were analyzed by HPLC-MS-MS(36) and the 
remaining samples were stored at -20°C until further use.  Immediately prior to analysis, 2 vials 
of ITC extract was resolubilized with 5 mL of 95% 33 mM sodium phosphate buffer (pH 6.5-7.0, 
containing 2 g/L ascorbic acid and 0.01 M magnesium chloride) and 5% tetrahydrofuran, and 
hydrolyzed by adding excess myrosinase.  The vial was sealed tightly and shaken for 3 hours at 
room temperature. 
 
Synthesis of N-acetyl cysteine derivatives of isothiocyanates: Before quantifying the ITCs in the 
extract, some samples were first conjugated to NAC as a method of stabilization (Figure 3.1).  
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This derivative was prepared by combining the strategies of previously published methods(53, 
54).  50 µL of pure ITCs (~ 1 mM) or freshly hydrolyzed ITC extracts from broccoli or broccoli 
sprouts were added to 1.9 ml 20 mM phosphate buffer (pH 8.5) containing approximately 5 
times molar excess NAC in a glass screw-top vial.  The vial was flushed with nitrogen, sealed, 
and allowed to react overnight at room temperature with shaking.  To protonate the carboxyl 
group, the pH was lowered to 2.5 with 1M hydrochloric acid, drop wise.  The conjugate was 
extracted 3 times with ethyl acetate, and the supernatants were pooled and dried under a stream 
of nitrogen gas in a 15-ml screw-top centrifuge tube.  The resulting residue was stored at -20 ˚C 
until ready to use. 
 
Total isothiocyanate quantification: The amount of total ITC was determined based on 
previously reported methods(54-56).  The samples were quantified using a standard curve of 1,3-
benzodithiole-2-thione (BTT).  BTT was synthesized by combining ~1 mM propyl ITC in 
methanol and 10-fold molar excess BDT in phosphate buffer (pH 8.5), and reacting for 2 hours at 
65°C.  The resulting solution was cooled to room temperature before extracting 3 times with 
methylene dichoride, pooling the extracts.  The methylene dichloride solution was saturated with 
sodium sulfate to remove any remaining water or water-soluble compounds.  The solution was 
filtered through a 0.2 µm nylon filter (Waters Associate, Milford, MA), dried under a stream of 
nitrogen gas, and stored at -20°C until ready to use.  Immediately before subjecting to HPLC 
analysis (20 µL injection), the BTT was resolubilized in 100 µL methylene dichloride and 4500 
µL methanol, vortex mixed, and again filtered with a 0.2 µm nylon filter.  The reaction scheme is 
shown in Figure 1.2.  50 µL of myrosinase-hydrolyzed broccoli or broccoli sprout extract, either 
free or conjugated with NAC (resolubilized in 50 µL methanol), and 500 µL of 100 mM 
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phosphate buffer (pH 8.5) were combined in an 11-ml glass screw-top vial.  The vial was flushed 
with argon, and 100 µL of 10 mM BDT in de-oxygenated methanol was added to the vial while 
continuously flushing with argon.  The tube was sealed, vortex mixed, and shaken for 2 hours at 
65°C.  It was then cooled to room temperature, centrifuged, and injected into the HPLC (40 µL). 
Analysis was performed on a Waters 2696 HPLC system equipped with a 996 photo-diode array 
(PDA) detector (Waters Associates, Milford, MA) using a 250 × 4.6 mm (5 µm) Luna C18 (2) 
reversed-phase column (Phenomenex Ltd., Torrance, CA) with a Phenomenex security guard 
column with a flow rate of 1 ml/min.  Injections were made into an 80% aqueous methanol 
mobile phase, and the eluants were monitored from 200 to 450 nm, quantifying at 365 nm. 
 
Extraction of glucosinolates and conversion to isothiocyanates for cell culture: GLUs were 
extracted with 70% aqueous methanol from freeze-dried organic broccoli and broccoli sprouts. 
The GLU extracts were either stored at -20 ˚C or hydrolyzed to ITCs using myrosinase.  The 
GLU extracts were quantified using LC-MS/MS (36), while the ITC extracts were quantified 
using the cyclocondensation assay (36). For ITC extracts used in the sulforhodamine B (SRB) 
assay, the GLUs were hydrolyzed with myrosinase and this solution directly applied to cells. 
 
Cell Culture: RT4, J82 and UMUC3 human bladder cancer cell lines were purchased from 
American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 medium (Gibco) 
supplemented with 10% fetal bovine serum, L-glutamine, penicillin and streptomycin.  Normal 
human bladder urothelial cells were purchased from Cambrex Bioscience Inc. (Walkersville, 
MD) through special contractual order and cultured in serum free, keratinocyte growth medium 
(KGM-2 SingleQuots), supplemented with BPE, hEGF, insulin, hydrocortisone, epinephrine, 
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transferrin and gentamicin/ amphoterecin-B from Cambrex. All cells were grown as monolayer 
cultures at 37 °C in a 95% air/5% CO2 humidified atmosphere.    
Cell Viability: To assess cell viability, cells were seeded in quadruplicate in 96-well plates at a 
density of 5,000 cells/well for normal bladder urothelial cells; 3,500 cells/well for RT4 and 1,000 
cells/well for J82 and UMUC3 in the aforementioned appropriated media for 1 week for normal 
cells and 24 hours for all other cells. Extracts Broccoli and broccoli sprout GLU and ITC extract 
treatments were performed at concentrations of 1X10-3, 1X10-2, 5.2X10-2, 0.10, 0.26, 0.52, and 
1.0 g of freeze-dried vegetable/L media for 48 hours. Concentrations were obtained by dilution 
in THF and media with a final THF concentration consistently at 0.125%. ITC extracts for both 
broccoli and broccoli sprouts were obtained from GLU extracts shaken with excess myrosinase 
in 95% 33 mM sodium phosphate buffer (pH 6.5-7.0, containing 2 g/L ascorbic acid and 0.01 M 
magnesium chloride) and 5% THF for 3 hours. Control cells were treated with the reaction 
mixture of sodium phosphate buffer and myrosinase. Pure phytochemicals R,S-Sulforaphane, 
Erucin (LKT laboratories, Inc.) Allyl ITC (Sigma-Aldrich) and Iberin (MP Biomedicals) 
treatments were performed at 0, 0.5, 1, 2.5, 5, 10, 20 µM of for 48 hours. Treatments were 
prepared as stock solutions in DMSO and diluted in culture medium for cell treatments. Control 
cells were treated with DMSO vehicle at a concentration equal to that of drug-treated cells (final 
DMSO concentration, ≤0.1% by volume). Normal urothelium cells, which divide more slowly 
than transformed, were exposed to 72 hours of treatment. Cell viability was then measured by 
SRB assay (Sulforhodamine B Based In Vitro Toxicology Assay Kit, Sigma) and percent cell 
viability was calculated. Experiments were performed in triplicate and data are represented as 
average ± standard deviation 
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Cell Cycle Analysis: Cells were seeded overnight in culture dishes at 1 X 106 /20mL of media for 
RT4 and 2 X 106/20mL of media for J82 or UMUC3 cells and treated with 0, 5, 10 or 20 µM 
concentrations of sulforaphane or erucin prepared as stock solutions in DMSO and diluted in 
culture medium for cell treatments for 48h. Cells were harvested by washing with Hanks 
Balanced Salt Solution (GIBCO), trypsinized and then resuspended in RPMI-1640 medium. 
Cells were centrifuged, media was removed and cells were washed in cold PBS, and then 
resuspended in 1mL of cold PBS and resuspended in 10mL of ice-cold 70% ethanol per sample 
and kept in a -20oC freezer overnight. Samples were then centrifuge, ethanol aspirated and cells 
resuspended in 1mL of staining buffer (14mL of PBS, 15 µL 0.1% Triton-X, 300µL DNAase-
free RNAase A, 750 µL Propidium Iodide). Samples were kept at room temperature for 30 
minutes and then analyzed by flow cytometry using a FACSCalibur (BD Biosciences, Franklin 
Lakes, NJ) instrument and data analysis using ModFit (Verity Software House, Topsham, ME). 
For sub-G1 population analysis, both floating and adherent cells were collected. Experiments 
were performed in quadruplicate and data are represented as average ± standard deviation 
Caspase- 3/7 assay:  Cells were seeded in quadruplicate in 96-well white-bottom plates at a 
density of 3,500 cells/well for RT4 and 1,000 cells/well for J82 and UMUC3 in RPMI-1640 
medium for 24 hours. They were then treated for 48 hours with increasing concentrations (0, 5, 
10, 20 µM) of R,S-Sulforaphane or Erucin (LKT laboratories, Inc.) or DMSO vehicle control. 
Caspase-3/7 activity was assessed by the Apo-ONE Homogenous Caspase-3/7 Assay, Promega. 
Experiments were performed in triplicate and data are represented as average ± standard 
deviation. 
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Western Blot Analysis: Cells were seeded overnight in culture dishes at 1 X 106 /20mL of media 
for RT4 and 2 X 106/20mL of media for J82 or UMUC3 cells and treated with 5, 10 or 20 µM 
concentrations of Sulforaphane or Erucin diluted in 10% FBS supplemented RPMI 1640 or 
DMSO vehicle at a concentration equal to that of drug-treated cells (final DMSO concentration, 
≤0.1% by volume) for 48 hours. Cells were collected and lysed in SDS Lysis buffer (Millipore). 
Tumor tissue protein extraction was performed using the T-PER Tissue Protein Extraction 
Reagent (Thermo Scientific) per the manufacturer’s protocol. Protein concentrations of the cell 
and tissue lysates were determined by using the BCA Protein Assay Kit (Thermo Scientific). 
SDS-PAGE was performed according to manufacturer’s protocols provided with NuPAGE pre-
cast gels (Invitrogen) and then transferred onto PVDF membranes (Invitrogen) Protein were 
visualized by chemiluminescence (Western Blotting Luminol Reagent, Santa Cruz).  Primary 
antibodies used were PARP, Survivin and GAPDH (Sigma).  Secondary antibodies were 
purchased from Santa Cruz. Densitometry using the ImageJ (NIH) program was utilized to 
quantify protein. Experiments were performed in triplicate and data are represented as average ± 
standard deviation. 
Dietary Preparation for In Vivo Experiment: For the broccoli sprout isothiocyanate extract diet, 
broccoli sprouts were boiled in water for 30 minutes. Sprouts were filtered out and extract was 
cooled, exogenous myrosinase added and mixture was incubated for 3.5 hours at 37˚C. The 
mixture was then flash frozen at -40˚C and then lyophilized and milled into a fine powder. Total 
Iberin, Sulforaphane and Erucin were quantified by LC-MS/MS.  For the broccoli sprout diet, 
broccoli sprouts were lyophilized and then ground into a fine powder. Glucoiberin, 
Glucoraphanin and Glucoerucin concentrations were quantified by LC-MS/MS. Broccoli ITC 
extract diet had 197 µmol ITC/g extract with 63% SFN, 28% Iberin and 8.4% Erucin. Broccoli 
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sprout diet had 51 µmol total GLU/ g sprout with 68.5% Glucoraphanin, 21% Glucoiberin and 
10.3% Glucoerucin. Broccoli sprout extract was mixed at 2% by weight into AIN 93G diet. 
Given that mice eat 3g diet/day and weigh on average 25g, they consumed 11.82 µmol total 
ITCs/day or 473 µmol total ITCs/kg body weight/day (297 µmol/kg bw SFN, 132 µmol/kg bw 
Iberin and 39.7 µmol/kg bw Erucin). Broccoli sprout diet as mixed at 4% by weight into 
AIN93G diet, and thus consumed 6.12 µmol total ITCs/day or 245 µmol total ITCs/kg body 
weight/day (171 µmol/kg bw glucoraphanin,  51 µmol/kg bw glucoiberin and 25.21 171 µmol/kg 
bw glucoerucin).  Diets were stored at -20 oC and food was changed every other day for the 
duration of the study (36). 
 
In vivo Study: Mouse xenograft studies were carried out with strict adherence to protocols 
approved by the Institutional Animal Care and Use Committee of The Ohio State University. 
Female athymic nude mice (FOXN1nu 4-5 weeks of age), were obtained from Harlan laboratories 
and acclimated on AIN93G pelleted diet for one week. Mice where then subcutaneously 
inoculated with 0.05 × 106 UMUC3, in 0.1 ml of Matrigel (BD Biosciences; 50% [v/v] in serum-
free medium), in the left and right dorsal flank. Three days after injection, mice were randomized 
into one of six treatment groups (12mice/group): 1) Vehicle Control Soybean Oil oral gavage 
once daily 2) 295 µmol/kg sulforaphane oral gavage once daily 3) 295 µmol/kg erucin oral 
gavage once daily 4)Control AIN 93G diet fed ad libitum 5) AIN 93 G diet + 4% Freeze-dried 
broccoli sprout fed ad libitum  6) AIN 93 G diet + 2% Freeze-dried broccoli sprout extract fed ad 
libitum. Mice were anesthetized with isofluorane prior to gavage treatments. Mouse weights and 
tumor sizes were measured biweekly with tumor volume determined by using calipers and 
volumes calculated using the standard formula: width2 × length × 0.52. Mice were sacrificed 
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when tumors reached a size of 1cm in either direction, or approximately 2 weeks. At sacrifice, 
blood was collected and plasma isolated. Tumors were removed and measured and weighed and 
bladders were also collected, with half of the tissue flash frozen in liquid nitrogen for protein 
extraction and the other half fixed overnight in 10% neutral buffered formalin and then 
transferred to 70% ethanol for histological use. Tumor and plasma was also reserved for 
metabolite quantification studies and metabolites were preserved by the addition of formic acid 
at a concentration of 0.2%.  
 
Histology: Formalin-fixed paraffin embedded tumor tissue from control and broccoli sprout 
treated mice were sectioned and stained with Hematoxylin and Eosin (H&E).  Ki67 staining was 
also performed and quantified. Briefly, antigen retrieval was performed by boiling the slides in 
citrate buffer (Antigen Retrieval Citra Plus, BioGenex, San Ramon, CA) for 15-30 minutes. The 
subsequent steps were completed in an OptiMax Automated Cell Staining System (BioGenex, 
San Ramon, CA) at room temperature. Endogenous peroxidase was inhibited by incubation in 
peroxide blocking solution (Dako Cytomation, Carpinteria, CA) for 5 min followed by 60 min 
incubation with Ki67primary antibody (1:50, rat monoclonal antibody, Dako Cytomation), 
biotinylated secondary antibodies and Vector ABC Elite kit (Vector Laboratories, Burlingame, 
CA) were then used.  Color was developed by 10 min incubation with DAB chromogen solution 
(Vector Laboratories).  Slides were counterstained with Mayers hematoxylin for 2 min and 
mounted.  The percentage of positive nuclei was then calculated based on the following formula: 
labeling index (%) = L / (L+C) x 100, where L= labeled cells and C = counterstained, unlabeled 
cells. 
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Metabolite Quantification:  Mercapturic acid pathway metabolites of sulforaphane and erucin 
were quantified by UPLC-MS/MS.  Plasma proteins were first precipitated with cold 
trifluoroacetic acid and 10uL of supernatant injected on a reversed phase UPLC column.  ITC 
metabolites were separated with a gradient of 0.1%formic acid versus 0.1%formic acid in 
acetonitrile andeluate interfaced with an electrospray probe to a triple quadrupole mass 
spectrometer in positive ion mode.  Respective molecular ions were fragmented by collision 
induced dissociation to characteristic fragment ions for detection.  Calibration curves were 
prepared for SFN and ECN conjugated to glutathione, cysteinyl glycine, cysteinyl or N-acetyl 
cysteine as well as free SFN. 
 
UPLC-MS/MS of ITC Metabolites:  To 100uL mouse blood plasmas on ice was added cold 
trifluoroacetic acid to 20%(v/v) to precipitate proteins.  Samples were centrifuged briefly and 
supernatant collected for injection on a UPLC-MS/MS system.  A 0.1%formic acid/0.1%formic 
acid in acetonitrile (A/B) mobile phase system was used to separate the  metabolites.  The initial 
condition was 0%B increased to 10%B over 1min, 10-33.3%B over 1.5min, 33.3-72%B over 
1.5min with 2 min for re-equilibration.  The eluent was interfaced with a triple quadrupole mass 
spectrometer via an electrospray probe in positive polarity.  Each metabolite was monitored as an 
MS/MS transition (parent>daughter ion) using collision induced dissociation.  Standards of ITC 
metabolites and free ITCs were purchased from Toronto Research Chemicals except for CysGly 
SFN and the erucin metabolites which were produced by reacting SFN or ERN isothiocyanates 
with their respective conjugating group (glutathione, cysteinyl glycine, cysteine or N-acetyl 
cysteine) and isolating them by preparative chromaotgraphy.  
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Statistics: Statistical significant was tested by two-tailed Student’s t-test or ANOVA, followed 
by the Student-Newman-Keuls multiple comparisions test, using Instat software (GraphPad). 
Significance was set at p ≤ 0.05. 
 
Results 
Quantification of glucosinolates in broccoli and broccoli sprout reveals broccoli sprouts have 
significantly higher levels than mature broccoli 
In order for in vitro and in vivo studies utilizing vegetable extracts to be meaningful, it is 
important to characterize the active phytochemicals present in these extracts, especially given 
their great variation found among plants. Given this, we utilized our previously developed LC-
MS/MS method  (37) to identify and quantify individual, intact glucosinolates (GLUs) in 
broccoli and broccoli sprouts (Table 1). We then hydrolzyed these GLU extracts into 
isothiocyanates (ITCs) using exogenous myrosinase and then quantified total ITCs utilizing a 
cyclocondensation reaction (Table 2). Significantly higher levels of total combined GLUs were 
detected in the broccoli and broccoli sprout extracts, 13.3 µmol and 84.6 µmol respectively.  
Glucoraphanin, the precursor to sulforaphane, was the predominant GLU found in both broccoli 
and broccoli sprouts, making up 64.4% and 52.6% of the total GLU composition, respectively.  
Aliphatic GLUs glucoiberin and glucoerucin, precursors of iberin and erucin, were the second 
and third highest GLUs in broccoli sprouts and indole GLUs glucobrassicin, precursor to indole-
3-carbinol and neoglucobrassicin were the second and third predominant GLUs in broccoli 
(Table 1).  As predicted, the amount of total converted isothiocyantes was significantly higher in 
broccoli sprouts over broccoli (Table 2).  
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Isothiocyanates extracts and pure phytochemicals significantly inhibit superficial and invasive 
human bladder cancer cell line viability 
We first wanted to test the potential biological activity of isothiocyanates in bladder cancer by 
testing whether broccoli and broccoli sprout glucosinolate and isothiocyanate extracts can inhibit 
superficial (RT4) and invasive (J82) human bladder cancer cell viability. We chose to utilize a 
Sulforhodamine B assay (SRB)  over the MTT or MTS assay due to the fact that these 
compounds have been shown to have antioxidant properties and the MTT/MTS assays are based 
on reductase enzyme activity while the SRB assay is based on staining cells and looking at total 
cell bulk, giving more accurate results. All treatments were performed for 48 hours. We found 
that glucosinolate extracts, from either broccoli or broccoli extracts, did not have an effect on 
cell growth on either cell line. However, ITC extracts caused a significant dose-dependent 
decrease in cell viability of both RT4 and J82 cell lines. Interestingly, mirroring our 
quantification data which shows that broccoli sprouts have significantly higher concentrations of 
ITCs, we see a significantly greater dose-dependent decrease in cell viability of both RT4 and 
J82 cells when treated with broccoli sprout ITC extract versus broccoli ITC extract (Fig 1A). We 
next wanted to determine of all isothiocyanates found in broccoli and broccoli sprouts, which is 
the most efficacious in inhibiting our bladder cancer cell lines. We chose to R,S Sulforaphane 
over purely R or S sulforaphane because our studies show that there is no significant effect of 
inhibition of cell viability of bladder cancer cell lines between these enantiomers. We found that 
in both superficial (RT4) and invasive (J82, UMUC3) cell lines, sulforaphane is the most potent 
inhibitor (IC50 = 11.5 µM in RT4 cells and IC50 = 5.8 µM in UMUC3 cells for 48 hours 
treatment). Erucin was the next compound with greatest efficacy (IC50 = 15.8 µM in RT4 cells 
and IC50 = 9.2 µM in UMUC3 cells for 48 hours treatment). This is followed by Allyl ITC and 
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then Iberin (Fig 1B). We then compared a panel of human bladder cell lines ranging from normal 
human urothelial cells (Normal HU) to superficial (RT4) to invasive (J82, UMUC3). We found 
that normal human urothelial cells are least sensitive to the inhibitory effects of sulforaphane and 
erucin, followed by superficial cells (RT4) and finally by invasive cells (J82 and UMUC3- J82 
data not shown) (Fig 1C). In summary, we found that broccoli and broccoli sprout glucosinolate 
extracts do not inhibit bladder cancer cell viability, while broccoli and broccoli sprout 
isothiocyanates do, with broccoli sprouts isothiocyanate extracts causing significantly greater 
inhibition due to their higher levels of isothiocyanates. Of all isothiocyanates, sulforaphane and 
erucin are the most potent inhibitors and normal human urothelial cells are least sensitive to 
these inhibitory effects, followed by superficial and then invasive.  
 
Sulforaphane and erucin treatment causes human bladder cancer cells to accumulate in the 
G2/M phase of the cell cycle 
 After determining that isothiocyanates have the ability to inhibit the viability of bladder cancer 
cell lines, we wished to further analyze how this inhibition is occurring. We first analyzed the 
effects of isothiocyanates sulforaphane and erucin on modulating the cell cycle of bladder cancer 
cells. We treated both non-invasive (RT4) and invasive (J82, UMUC3 – UMUC3 data not 
shown) cells with either vehicle control (DMSO), 5, 10 and 20 SFN or ECN µM for 48 hours 
and observed the status of cells in the cell cycle after treatment. We observed a significant, dose-
dependent accumulation of cells in the G2/M phase. The S phase accumulation was not 
significantly altered.  SFN and ECN altered the cell cycle in a similar way and to a comparable 
extent (Fig 2). 
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Apoptosis is significantly induced when bladder cancer cells are treated with sulforaphane 
and erucin 
To further evaluate how isothiocyanates can inhibit the viability of bladder cancer cell lines, we 
studied whether these compounds can induce apoptosis.  We utilized a caspase 3/7 activity assay 
and also looked at PARP, one of the cleaved proteins of caspase 3/7 enzymes. We also looked at 
expression of survivin, an important anti-apoptotic protein and a good predictor of bladder 
cancer disease progression  (38). Upon treatment with SFN or ECN for 48hours, in both non-
invasive (RT4) and invasive (J82, UMUC3) cells, we saw a significant dose-dependent increase 
in caspase 3/7 activity (Fig 3A). We also observed a significant dose-dependent induction of 
PARP cleavage and a dose-dependent decrease of survivin expression (Fig 3B). Together this 
data strongly suggests that broccoli and broccoli sprout isothiocyanates, particularly 
sulforaphane and erucin, can significantly inhibit both superficial and invasive bladder cancer 
cell viability and that this inhibition is due to accumulation of cells in the G2/M phases of the 
cell cycle as well as the induction of apopotsis.  
 
Broccoli sprout isothiocyanates significantly inhibit bladder cancer and induce apoptosis in 
vivo 
After determining the inhibitory effects of broccoli isothiocyanates in vitro, we wanted to 
translate our work into an in vivo xenograft model. We injected female athymic nude mice with 
UMUC3, invasive human bladder cancer cells and exposed them to one of six treatments: 
Control AIN93G diet, 2% broccoli sprout isothiocyanate extract diet, 4% broccoli sprout diet, 
Control soybean oil gavage, 295 µmol/kg body weight sulforaphane gavage and 295 µmol/kg 
body weight erucin gavage. Before being incorporated into the diet, broccoli sprout GLUs and 
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broccoli sprout extract ITCs were quantified by UPLC/MS-MS. We wished to compare how a 
dietary administration versus a pure compound treatment would effect tumor growth. We utilized 
previously published work using broccoli sprout extract at 160 µmol/kg body weight/day in a 
bladder cancer model in rats to help guide us in determining what concentration of broccoli 
sprout isothiocyanates to utilize (24). Given previous findings that rats absorb isothiocyanates 
more efficiently than mice, and to best match total sulforaphane in our broccoli sprout extract 
diet (297 µmol/kg bw/day) we decided to sulforaphane at 296 µmol/kg bw/day in our study (39). 
Encouraged by our in vitro data, we matched this concentration in our erucin treatment to 
compare the efficacy of erucin to sulforaphane in vivo. We matched to the best of our ability, 
total glucosinolate content in the broccoli sprout diet with total isothiocyanate content in the 
broccoli sprout isothiocyanate without making the percentage of broccoli sprout in our diet 
unreasonable and not practical for incorportation into human diets in the future, thus we chose 
4% over 8% (giving a total ITC concentration of 245 µmol GLU/ kg bw/day containing 172 
µmol/kg bw/day of glucoraphanin, the precursor of sulforaphane).  Mice were treated for two 
weeks, where mouse weight and tumor growth rate was monitored, and were then sacrificed, and 
tumors harvested and weighed. We saw a significant inhibition (40% or greater) of tumor weight 
in all treated groups, with the most significant inhibition seen in the erucin treated group. There 
was no significant change in mouse weight through the study (data not shown). Interestingly, 
broccoli sprout and broccoli sprout isothiocyanate extract groups exhibited similar inhibition. 
Growth rate was also inhibited in all groups following similar trends to the final tumor weight 
data (Fig 4A). We next performed Ki67 staining, to determine how cell proliferation was 
effected by broccoli sprout diet treatment. We saw a significant decrease in % positive cells 
stained with Ki67, suggesting that cell proliferation was significantly inhibition with broccoli 
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sprout treatment. (Fig 4B). In addition, we wished to test our in vitro findings of an induction of 
apopotsis with broccoli isothiocyanate treatments in vivo, and thus we looked at PARP cleavage, 
an indication of caspase 3/7 activity and saw a significant increase in cleaved PARP protein in 
broccoli sprout treated group when compared to control (Fig 4B). These data further support the 
ability of broccoli isothiocyanates to inhibit bladder cancer. 
 
Isothiocyanates administered by diet or pure gavage are efficiently absorbed into the blood 
We found metabolites of sulforaphane and erucin were absent in control mice and present in 
plasma of all treated groups, with dietary and pure phytochemical treatments resulting in similar 
plasma metabolite concentrations (micromolar range). There was also significant absorption of 
broccoli isothiocyanates in tumor and bladder tissue. Interestingly, broccoli sprout diets lead to 
very similar plasma concentrations when compared to hydrolyzed broccoli sprout ITC extracts 
(Fig 5). N-acetylcysteine conjugates were found at highest concentrations, followed by cysteine 
and gluathione conjugates and small amounts of detectable cysteinylglycine conjugates and free 
sfn. Interestingly, we observed a robust interconversion of sulforaphane and erucin, as both 
metabolites were present in the blood of mice fed pure individual compounds. 
 
Discussion 
 The goal of our study was to determine if broccoli isothiocyanates have the ability to 
inhibit bladder cancer in vitro and in vivo and to determine the metabolism and bioavailability of 
these compounds in tumor and bladder tissue. There have been a handful of studies looking at 
the ability of isothiocyanates to modulate bladder carcinogenesis in vivo. One of the most recent 
looked at the effect of allyl isothiocyanate rich mustard seed powder (71.5 mg/kg giving from a 
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singirin dose of 9 µnmol/kg) in an orthotopic rat bladder cancer model and found a 34.5% 
inhibition of bladder cancer growth and blocked muscle invasion (40).  Another study showed 
that sulforaphane can inhibit 4-aminobiphenyl-induced DNA damage in RT4 cells and in bladder 
tissue (41). In a long term (36 week) rat study, animals were fed 40 or 160 µmol/kg bw/day 
broccoli sprout extract and were given 0.05% N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in 
the drinking water, a specific bladder carcinogen which produces bladder cancer which 
histologically resembles human bladder cancer. A significant decrease in incidence, multiplicity, 
size and progression of bladder cancer was observed in the broccoli extract treated group, 
particularly at the 160 µmol/kg concentration. This was partly attributed to the broccoli extract’s 
ability to significantly induce glutathione-S-transferase and NAD(P)H: quinine oxidoreductase 1, 
enzymes that detoxicify oxidants and carcinogens (24). The uniqueness of our finding is that we 
were able to show that this inhibition is independent of the ability of isothiocyanates to detoxify 
carcinogens and prevent DNA damage (24, 41) due to the fact that the cancer cells were already 
established in a xenograft model and our model was carcinogen induced. This suggests that other 
mechanisms of action are at play which gives isothiocyanates the ability to have an anti-bladder 
cancer effects. 
 
 The amount of GLUs in both the broccoli and broccoli sprout extracts was consistent 
with that found in the literature (Table 1 and 2) (36). Generally, mature plants have fewer GLUs 
than immature plants because the GLUs are both hydrolyzed by myrosinase or diluted as the 
plant grows (42).  The mechanism for indole GLUs’ increase as the plant matures is still 
unknown, but it has previously been estimated that there are 50% more indole GLUs in mature 
broccoli than immature (17). In our cell viability data with broccoli and broccoli sprout GLU and 
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ITC extracts, where ITC extracts were made by adding exogenous myrosinase to the GLU 
extracts, it was apparent that GLU do not have an effect on bladder cancer cell viability while 
ITCs do, providing strong evidence for the activity of ITCs in bladder cancer (Fig 1A). This may 
at least partly explain epidemiological observation of increased broccoli consumption correlating 
with decreased bladder cancer risk (12, 43). We showed that sulforaphane and erucin can both 
induce significant accumulation of bladder cancer cells in the G2/M phase (Fig 2). This mirrors 
previous findings which shows that broccoli sprout extract can induce cell cycle arrest in the 
G2/M and S phase through downregulation of Cdc25c and disruption of the mitotic spindle (22). 
For the first time, we were able to show that not only do broccoli sprout isothiocyanate extract 
and sulforaphane have the ability to inhibit bladder cancer in vivo, but broccoli sprouts and 
erucin also have this ability with comparable or even greater efficacy (Fig 4). Our 4% broccoli 
sprout diet had half the amount of total precursor glucosinolates than our 2% broccoli sprout ITC 
extract diet, however, the inhibitory effects seen were comparable. This could suggest that either 
there is something in the broccoli sprouts that was not present in the broccoli sprout 
isothiocyanate extract that may be exerting inhibitory effects, working with the converted 
isothiocyanates, or it could also suggest that the total amount of absorbed isothiocyanates was 
saturated and giving a higher dose of ITCs did not exert a more potent effect (Fig 4). Our 
metabolite data suggests the latter possibility due to the fact that broccoli sprout ITC extract diet 
and broccoli sprout diet had similar total metabolite levels (Fig 5). Erucin showed strong 
activity, having comparable or greater efficacy than sulforaphane in the inhibition of badder 
cancer cell viability, modulation the cell cycle, induction of apoptosis and inhibiting bladder 
tumor growth (Fig 2-4). Erucin was also well absorbed in the plasma (Fig 5). Given our 
observation of the robust interconversion of sulforaphane to erucin and vice versa in vivo it is 
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interesting to consider which of these compounds are inducing these effects (Fig 5).  We showed 
that normal cells are less sensitive to the inhibitory effects of these compounds compared to 
superficial and invasive human bladder cancer cells. In addition, treatment with isothiocyanates 
did not show any toxicity, organs were of normal size and histology and there was no significant 
difference in mouse weight throughout the study (data not shown).  
 Isothiocyanates have also been shown to have bladder cancer inducing properties, 
particularly phenethyl isothiocyanate (PEITC) and benzyl isothiocyanate (BITC). Both pre- and 
post- initiation events were studied. Pre-initiation, 0.1% PIETC or BITC for 14 days lead to 
increased inflammatory cell infiltration and hyperplasia of the bladder epithelium (44). In 
addition, post-initiation effects of 0.1 % PEITC and BITC were examined in urinary bladder 
carcinogenesis with or without pre-treatment with diethylnitrosamine (DEN) and BBN, and both 
isothiocyanates showed strong promoter and some complete carciniogenic potential of bladder 
cancer (45). One possible reason for this observation could be the accumulated dose of urinary 
ITCs with this dosing regimen. It is estimated that NAC-ITCs could have been constantly 
maintained at levels far greater than 1 mmol/L and that although ITCs can be beneficial at 
preventing or inhibiting bladder cancer growth at lower doses, at excessively higher doses, they 
may be harmful (21). In addition, it is possible that the benzyl or phenethyl isothiocyanates may 
have some harmful effects but not other ITCs such as sulforaphane or erucin. Broccoli and 
broccoli sprouts do not have appreciable levels of these isothiocyanates and may be a better 
option over cruciferous vegetables containing higher levels of PIETC or BITC such as 
cauliflower, cabbage or Brussels sprouts, especially if these compounds are used in high doses 
for prevention of treatment of bladder cancer (46). In our study we showed that 295 µmol/kg 
bw/day of either sulforaphane or erucin, or 2% broccoli sprout extract (total ITCs = 473 µmol/kg 
 25
bw/day) or 4% broccoli sprout diet (total GLUs = 245 µmol/kg bw/day) was both safe and 
efficacious at inhibiting bladder cancer (Fig 4), at least in a two week time span. It would be 
beneficial to test these levels of isothiocyanates in a long term transgenic bladder cancer model 
to test the ability of these compounds to inhibit non-carcinogen induced bladder cancer, without 
inducing long term toxic effects (47-52). 
 There are several potential preventative approaches which can be employed in humans if 
broccoli shows strong promise in inhibiting bladder cancer pre-clinically.  One means would be 
through a primary prevention strategy. Here, recommendations to the general public or to 
individuals at higher risk, such as smokers or those with occupational exposures, can be used to 
advise individuals to more frequently consume cruciferous vegetables to help prevent the 
development of bladder cancer. Another approach is a secondary prevention strategy, where 
patients who have already undergone surgical resection of non-invasive cancer would be given 
cruciferous vegetables, through dietary (foods and novel food products) or perhaps 
pharmacologic products, in order to help prevent recurrence of their disease.  This could 
significantly contribute to lowering health care costs, which are high due to monitoring 
(cystoscopic exams) and treating these patients (intravesical immunotherapy and chemotherapy), 
as well as help alleviate patient suffering. Our future hope for these compounds is to use these in 
a secondary chemoprevention approach to help ameliorate the bladder cancer burden. 
 
Acknowledgments: Rob Rengel, Sanjay Bhave, Valerie DeGroff, Jennifer Thomas-Ahner 
 
 
 
 26
References: 
1. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. Global cancer statistics, 2002. CA 
Cancer J Clin, 55: 74-108, 2005. 
 
2. Botteman, M. F., Pashos, C. L., Hauser, R. S., Laskin, B. L., and Redaelli, A. Quality of 
life aspects of bladder cancer: a review of the literature. Qual Life Res, 12: 675-688, 
2003. 
 
3. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J 
Clin, 52: 23-47, 2002. 
 
4. Mitra, A. P. and Cote, R. J. Molecular pathogenesis and diagnostics of bladder cancer. 
Annu Rev Pathol, 4: 251-285, 2009. 
 
5. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., and Hauser, R. The health 
economics of bladder cancer: a comprehensive review of the published literature. 
Pharmacoeconomics, 21: 1315-1330, 2003. 
 
6. Augustine, A., Hebert, J. R., Kabat, G. C., and Wynder, E. L. Bladder cancer in relation 
to cigarette smoking. Cancer Res, 48: 4405-4408, 1988. 
 
7. Brennan, P., Bogillot, O., Cordier, S., Greiser, E., Schill, W., Vineis, P., Lopez-Abente, 
G., Tzonou, A., Chang-Claude, J., Bolm-Audorff, U., Jockel, K. H., Donato, F., Serra, C., 
Wahrendorf, J., Hours, M., T'Mannetje, A., Kogevinas, M., and Boffetta, P. Cigarette 
smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J 
Cancer, 86: 289-294, 2000. 
 
8. Crawford, J. M. The origins of bladder cancer. Lab Invest, 88: 686-693, 2008. 
 
9. Wu, X. R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer, 5: 
713-725, 2005. 
 
10. La Rochelle, J., Kamat, A., Grossman, H. B., and Pantuck, A. Chemoprevention of 
bladder cancer. BJU Int, 102: 1274-1278, 2008. 
 
11. Michaud, D. S., Spiegelman, D., Clinton, S. K., Rimm, E. B., Curhan, G. C., Willett, W. 
C., and Giovannucci, E. L. Fluid intake and the risk of bladder cancer in men. N Engl J 
Med, 340: 1390-1397, 1999. 
 
12. Michaud, D. S., Spiegelman, D., Clinton, S. K., Rimm, E. B., Willett, W. C., and 
Giovannucci, E. L. Fruit and vegetable intake and incidence of bladder cancer in a male 
prospective cohort. J Natl Cancer Inst, 91: 605-613, 1999. 
 
13. Michaud, D. S., Spiegelman, D., Clinton, S. K., Rimm, E. B., Willett, W. C., and 
Giovannucci, E. Prospective study of dietary supplements, macronutrients, 
 27
micronutrients, and risk of bladder cancer in US men. Am J Epidemiol, 152: 1145-1153, 
2000. 
 
14. Michaud, D. S., Clinton, S. K., Rimm, E. B., Willett, W. C., and Giovannucci, E. Risk of 
bladder cancer by geographic region in a U.S. cohort of male health professionals. 
Epidemiology, 12: 719-726, 2001. 
 
15. Fahey, J. W., Zalcmann, A. T., and Talalay, P. The chemical diversity and distribution of 
glucosinolates and isothiocyanates among plants. Phytochemistry, 56: 5-51, 2001. 
 
16. Shapiro, T. A., Fahey, J. W., Wade, K. L., Stephenson, K. K., and Talalay, P. 
Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and 
excretion in humans. Cancer Epidemiol Biomarkers Prev, 10: 501-508, 2001. 
 
17. Verkerk, R., Schreiner, M., Krumbein, A., Ciska, E., Holst, B., Rowland, I., De Schrijver, 
R., Hansen, M., Gerhauser, C., Mithen, R., and Dekker, M. Glucosinolates in Brassica 
vegetables: the influence of the food supply chain on intake, bioavailability and human 
health. Mol Nutr Food Res, 53 Suppl 2: S219, 2009. 
 
18. Fahey, J. W., Zhang, Y., and Talalay, P. Broccoli sprouts: an exceptionally rich source of 
inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S 
A, 94: 10367-10372, 1997. 
 
19. Clarke, J. D., Dashwood, R. H., and Ho, E. Multi-targeted prevention of cancer by 
sulforaphane. Cancer Lett, 269: 291-304, 2008. 
 
20. Bheemreddy, R. M. and Jeffery, E. H. The metabolic fate of purified glucoraphanin in 
F344 rats. J Agric Food Chem, 55: 2861-2866, 2007. 
 
21. Tang, L. and Zhang, Y. Dietary isothiocyanates inhibit the growth of human bladder 
carcinoma cells. J Nutr, 134: 2004-2010, 2004. 
 
22. Tang, L., Zhang, Y., Jobson, H. E., Li, J., Stephenson, K. K., Wade, K. L., and Fahey, J. 
W. Potent activation of mitochondria-mediated apoptosis and arrest in S and M phases of 
cancer cells by a broccoli sprout extract. Mol Cancer Ther, 5: 935-944, 2006. 
 
23. Singh, A. V., Xiao, D., Lew, K. L., Dhir, R., and Singh, S. V. Sulforaphane induces 
caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards 
growth of PC-3 xenografts in vivo. Carcinogenesis, 25: 83-90, 2004. 
 
24. Munday, R., Mhawech-Fauceglia, P., Munday, C. M., Paonessa, J. D., Tang, L., Munday, 
J. S., Lister, C., Wilson, P., Fahey, J. W., Davis, W., and Zhang, Y. Inhibition of urinary 
bladder carcinogenesis by broccoli sprouts. Cancer Res, 68: 1593-1600, 2008. 
 
 28
25. Myzak, M. C., Tong, P., Dashwood, W. M., Dashwood, R. H., and Ho, E. Sulforaphane 
retards the growth of human PC-3 xenografts and inhibits HDAC activity in human 
subjects. Exp Biol Med (Maywood), 232: 227-234, 2007. 
 
26. Dashwood, R. H. and Ho, E. Dietary histone deacetylase inhibitors: from cells to mice to 
man. Semin Cancer Biol, 17: 363-369, 2007. 
 
27. Kassie, F., Anderson, L. B., Scherber, R., Yu, N., Lahti, D., Upadhyaya, P., and Hecht, S. 
S. Indole-3-carbinol inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus 
benzo(a)pyrene-induced lung tumorigenesis in A/J mice and modulates carcinogen-
induced alterations in protein levels. Cancer Res, 67: 6502-6511, 2007. 
 
28. Cornblatt, B. S., Ye, L., Dinkova-Kostova, A. T., Erb, M., Fahey, J. W., Singh, N. K., 
Chen, M. S., Stierer, T., Garrett-Mayer, E., Argani, P., Davidson, N. E., Talalay, P., 
Kensler, T. W., and Visvanathan, K. Preclinical and clinical evaluation of sulforaphane 
for chemoprevention in the breast. Carcinogenesis, 28: 1485-1490, 2007. 
 
29. Shapiro, T. A., Fahey, J. W., Dinkova-Kostova, A. T., Holtzclaw, W. D., Stephenson, K. 
K., Wade, K. L., Ye, L., and Talalay, P. Safety, tolerance, and metabolism of broccoli 
sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer, 55: 53-
62, 2006. 
 
30. Kensler, T. W., He, X., Otieno, M., Egner, P. A., Jacobson, L. P., Chen, B., Wang, J. S., 
Zhu, Y. R., Zhang, B. C., Wang, J. B., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., 
Fang, X., Li, Y. F., Yu, L. Y., Prochaska, H. J., Davidson, N. E., Gordon, G. B., Gorman, 
M. B., Zarba, A., Enger, C., Munoz, A., Helzlsouer, K. J., and et al. Oltipraz 
chemoprevention trial in Qidong, People's Republic of China: modulation of serum 
aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev, 7: 127-134, 
1998. 
 
31. Fahey, J. W. and Talalay, P. Antioxidant functions of sulforaphane: a potent inducer of 
Phase II detoxication enzymes. Food Chem Toxicol, 37: 973-979, 1999. 
 
32. Myzak, M. C., Hardin, K., Wang, R., Dashwood, R. H., and Ho, E. Sulforaphane inhibits 
histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. 
Carcinogenesis, 27: 811-819, 2006. 
 
33. Myzak, M. C., Dashwood, W. M., Orner, G. A., Ho, E., and Dashwood, R. H. 
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-
minus mice. Faseb J, 20: 506-508, 2006. 
 
34. Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., and Robson, C. N. 
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. 
Prostate, 59: 177-189, 2004. 
 
 29
35. Mellon, F. A., Bennett, R. N., Holst, B., and Williamson, G. Intact glucosinolate analysis 
in plant extracts by programmed cone voltage electrospray LC/MS: performance and 
comparison with LC/MS/MS methods. Anal Biochem, 306: 83-91, 2002. 
 
36. Tian, Q., Rosselot, R. A., and Schwartz, S. J. Quantitative determination of intact 
glucosinolates in broccoli, broccoli sprouts, Brussel sprouts, and cauliflower by high-
performance liquid chromatography-electrospray ionization-tandem mass spectrometry. 
Anal Biochem, 343: 93-99, 2005. 
 
37. Tian, Q., Rosselot, R. A., and Schwartz, S. J. Quantitative determination of intact 
glucosinolates in broccoli, broccoli sprouts, Brussels sprouts, and cauliflower by high-
performance liquid chromatography-electrospray ionization-tandem mass spectrometry. 
Anal Biochem, 343: 93-99, 2005. 
 
38. Rosenblatt, R., Jonmarker, S., Lewensohn, R., Egevad, L., Sherif, A., Kalkner, K. M., 
Nilsson, S., Valdman, A., and Ullen, A. Current status of prognostic 
immunohistochemical markers for urothelial bladder cancer. Tumour Biol, 29: 311-322, 
2008. 
 
39. Ioannou, Y. M., Burka, L. T., and Matthews, H. B. Allyl isothiocyanate: comparative 
disposition in rats and mice. Toxicol Appl Pharmacol, 75: 173-181, 1984. 
 
40. Bhattacharya, A., Tang, L., Li, Y., Geng, F., Paonessa, J. D., Chen, S. C., Wong, M. K., 
and Zhang, Y. Inhibition of bladder cancer development by allyl isothiocyanate. 
Carcinogenesis, 31: 281-286. 
 
41. Ding, Y., Paonessa, J. D., Randall, K. L., Argoti, D., Chen, L., Vouros, P., and Zhang, Y. 
Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and 
tissues. Carcinogenesis, 31: 1999-2003. 
 
42. Farnham, M. W., Wilson, P. E., Stephenson, K. K., and Fahey, J. W. Genetic and 
environmental effects on glucosinolate content and chemoprotective potency of broccoli. 
Plant Breeding, 123: 60-65, 2004. 
 
43. Nagano, J., Kono, S., Preston, D. L., Moriwaki, H., Sharp, G. B., Koyama, K., and 
Mabuchi, K. Bladder-cancer incidence in relation to vegetable and fruit consumption: a 
prospective study of atomic-bomb survivors. Int J Cancer, 86: 132-138, 2000. 
 
44. Akagi, K., Sano, M., Ogawa, K., Hirose, M., Goshima, H., and Shirai, T. Involvement of 
toxicity as an early event in urinary bladder carcinogenesis induced by phenethyl 
isothiocyanate, benzyl isothiocyanate, and analogues in F344 rats. Toxicol Pathol, 31: 
388-396, 2003. 
 
45. Hirose, M., Yamaguchi, T., Kimoto, N., Ogawa, K., Futakuchi, M., Sano, M., and Shirai, 
T. Strong promoting activity of phenylethyl isothiocyanate and benzyl isothiocyanate on 
urinary bladder carcinogenesis in F344 male rats. Int J Cancer, 77: 773-777, 1998. 
 30
 
46. VanEtten, C. H., Daxenbichler, M. E., Williams, P. H., and Kwolek, W. F. 
Glucosinolates and derived products in cruciferous vegetables. Analysis of the edible part 
from twenty-two varieties of cabbage. J Agric Food Chem, 24: 452-455, 1976. 
 
47. Buckley, M. T., Yoon, J., Yee, H., Chiriboga, L., Liebes, L., Ara, G., Qian, X., Bajorin, 
D. F., Sun, T. T., Wu, X. R., and Osman, I. The histone deacetylase inhibitor belinostat 
(PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med, 5: 
49, 2007. 
 
48. Mo, L., Zheng, X., Huang, H. Y., Shapiro, E., Lepor, H., Cordon-Cardo, C., Sun, T. T., 
and Wu, X. R. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, 
triggers bladder tumorigenesis. J Clin Invest, 117: 314-325, 2007. 
 
49. Wu, X. R. Biology of urothelial tumorigenesis: insights from genetically engineered 
mice. Cancer Metastasis Rev, 28: 281-290, 2009. 
 
50. Wu, X. R., Lin, J. H., Walz, T., Haner, M., Yu, J., Aebi, U., and Sun, T. T. Mammalian 
uroplakins. A group of highly conserved urothelial differentiation-related membrane 
proteins. J Biol Chem, 269: 13716-13724, 1994. 
 
51. Zhang, Z. T., Pak, J., Huang, H. Y., Shapiro, E., Sun, T. T., Pellicer, A., and Wu, X. R. 
Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. 
Oncogene, 20: 1973-1980, 2001. 
 
52. Zhang, Z. T., Pak, J., Shapiro, E., Sun, T. T., and Wu, X. R. Urothelium-specific 
expression of an oncogene in transgenic mice induced the formation of carcinoma in situ 
and invasive transitional cell carcinoma. Cancer Res, 59: 3512-3517, 1999. 
 
53. Vermeulen, M., Zwanenburg, B., Chittenden, G. J. F., and Verhagen, H. Synthesis of 
isothiocyanate-derived mercapturic acids. European J Medicinal Chem, 38: 729-737, 
2003. 
 
54. Zhang, Y., Wade, K. L., Prestera, T., and Talalay, P. Quantitative determination of 
isothiocyanates, dithiocarbamates, carbon disulfide, and related thiocarbonyl compounds 
by cyclocondensation with 1,2-benzenedithiol. Anal Biochem, 239: 160-167, 1996. 
 
55. Choi, M. M. F., Shuang, S., Lai, H. Y., Cheng, S. C., Cheng, R. C. W., Cheung, B. K. B., 
and Lee, A. W. M. Gas chromatography-mass spectrometric determination of total 
isothiocyanates in Chinese medicinal herbs. Anal Chim Acta, 516: 155-163, 2004. 
 
56. Jiao, D., Yu, M. C., Hankin, J. H., Low, S., and Chung, F. Total isothiocyanate contents 
in cooked vegetables frequently consumed in Singapore. J Agric Food Chem, 46: 1055-
1058, 1998. 
 
 
 31
 
Glucosinolate Corresponding ITC Broccoli Broccoli Sprout
 mol/g dry % of total  mol/g dry % of total
Glucoraphanin Sulforaphane 8.53 64.4 44.5 52.6
Glucoiberin Iberin 0.03 0.23 21.3 25.2
Singrin Allyl ITC 0 0 0.51 0.60
Glucoerucin Erucin 0.01 0.08 9.02 10.7
Glucobrassicin Indole-3-carbinol 2.19 16.5 0.54 0.64
Progoitrin n/a 0 0 3.08 3.64
Gluconapin n/a 0.15 1.11 1.34 1.59
Glucoalysin n/a 0.06 0.45 0.06 0.08
Neoglucobrassicin n/a 1.9 14.3 1.96 2.31
4-methoxy 
glucobrassicin
n/a 0.41 3.08 1.54 1.82
Gluconapoleiferin n/a 0.02 0.15 0.76 0.90
Total 13.3 100 84.6 100  
 
Table 1: Characterization of glucosinolates in broccoli and broccoli sprout extracts, as 
quantified by HPLC-MS/MS. Broccoli sprouts have significantly higher levels of total 
glucosinolates than broccoli. Values represent the mean of two samples. 
 
 
 
 
 
Vegetable Total non-indole GLUs 
(µmol/g)
 *
 
Total ITCs  
(µmol/g)
 *
 
% GLU converted to 
ITC 
Broccoli 8.78 
 
6.65 ± 0.65 75.7 ± 0.9 
Broccoli Sprout 80.6 
 
96.0 ± 13.1 119 ± 11 
 
 
Table 2:  Amount of total combined non-indole GLUs, ITCs, and percent conversion of 
GLUs to ITCs in broccoli and broccoli sprout extracts.  Values represent the mean ± SD 
(n=4).  
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Figure 1: Broccoli and broccoli sprout isothiocyanates significanctly inhibit human bladder 
cancer cell lines. Growth inhibitory effects of broccoli and broccoli sprout glucosinolates and 
isothiocayantes were assessed by Sulforhodamine B assay (SRB), 48 hours of treatment. A. The 
effect of glucosinolates and enzymatically-hydrolyzed glucosinolates (isothiocyanates) extracted 
from broccoli and broccoli sprouts on the cell viability of RT4 (superficial) and J82 (invasive) 
human bladder cancer cell lines.  Percent cell viability was calculated by (absorbance of the 
treatment wells x 100) / absorbance of the control.  B. Isothiocyanates found in broccoli and 
broccoli sprout extracts (sulforaphane, erucin, allyl ITC, iberin) were compared for efficacy in 
RT4 (superficial) and UMUC3 (invasive) cell lines. C. Sulforaphane and Erucin treatment was 
compared in a panel of human bladder cells ranging from normal human urothelial (Normal 
HU), superficial bladder cancer (RT4) and invasive (J82, UMUC3). Data represents the means of 
three independent experiments with error bars representing standard deviations. 
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Figure 2: Sulforaphane and erucin treatment leads to cell cycle alteration of human 
bladder cancer cells. RT4 (superficial) and J82 (invasive) human bladder cancer cells were 
treated with vehicle control (DMSO) or 5, 10 and 20 µM of sulforaphane (SFN) or erucin (ECN) 
for 48 hours and then stained with propidium iodide for cell cycle analysis through flow 
cytometry. Data represents the means of four independent experiments ± SD.  
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Figure 3: Sulforaphane and erucin treatment causes apoptosis in human bladder cancer 
cell lines. Superficial (RT4) and Invasive (J82, UMUC3) bladder cancer cells were treated with 
increasing doses of sulforaphane (SFN) or erucin (ECN) for 48 hours A. Caspase 3/7 activity was 
assessed through Promega Apo-ONE ® Homogenous Caspase 3/7 fluorescence assay. B. 
Cleavage of PARP, an indicator of apoptosis, and expression of survivin, an antiapoptotic protein 
was assessed through western blot analysis and quantified through densitometry. Data represents 
the means of three independent experiments with error bars representing standard deviations 
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Figure 4: Broccoli isothiocyanates cause inhibition of bladder cancer and induction of 
apoptosis in vivo. Female athymic nude mice were injected with UMUC3 (invasive) human 
bladder cancer cells in each flank (2 tumors per mice) and treated with either Vehicle Control 
Soybean Oil oral gavage once daily 2) 295 µmol/kg sulforaphane oral gavage once daily 3) 295 
µmol/kg erucin oral gavage once daily 4)Control AIN 93G diet fed ad libitum 5) AIN 93 G diet 
+ 4% Freeze-dried broccoli sprout fed ad libitum  6) AIN 93 G diet + 2% Freeze-dried broccoli 
sprout extract fed ad libitum. Treatments were administered for 2 weeks, before tumors could 
reach greater than 1cm in any direction A. At sacrifice, tumors were harvested and weighed and 
final tumor weights were compared between groups. Tumor growth rates were also monitored 
during the time of treatment and compared. Data represents box plots of median and min and 
 36
max values with * p<0.05, ***p<0.001 for tumor weights and mean with error bars representing 
standard error. B. Tumors from control diet and broccoli sprout diet treated mice were fixed, 
embedded, sectioned and stained with hematoxylin and eosin (H&E) or Ki67 with background 
hematoxylin stain, a marker of proliferation. Ki67 was quantified as percent positive cells. 
Cleaved PARP was compared in control versus broccoli sprout treated groups and quantified. 
Data represents five independent samples and error bars represent standard deviation.  
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Figure 5. Profiles of SFN and ECN metabolites in mouse plasmas from 2%BSx (broccoli sprout 
glucosinolates converted to ITC), 4%fd BS (freeze dried broccoli sprouts), sfn gav (gavage with 
SFN in soybean oil), ecn gav (gavage with erucin in soybean oil) and total ITC metabolite levels 
per group.   
 
